CDT Equity Inc. (CDT)
| Market Cap | 5.05M +11.4% |
| Revenue (ttm) | n/a |
| Net Income | -39.22M |
| EPS | -1,177.90 |
| Shares Out | 4.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46,118,722 |
| Open | 1.100 |
| Previous Close | 0.950 |
| Day's Range | 0.933 - 2.890 |
| 52-Week Range | 0.793 - 848.000 |
| Beta | 1.57 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 12, 2026 |
About CDT
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also ... [Read more]
Financial Performance
Financial StatementsNews
CDT Equity receives Nasdaq notice for delayed quarterly report
CDT Equity (CDT) announced it received a notice from Nasdaq indicating it is not in compliance with listing rules due to a delay in filing its Quarterly Report on Form…
CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that the Company received a written notice (“Notice...
CDT Equity granted Canadian patent for AZD5904 in male infertility
CDT Equity (CDT) announced that the patent covering the use of AZD5904 in male infertility has now been granted in Canada, completing the approval of this patent in all key…
CDT Announces Canadian Patent for AZD5904 in Male Infertility
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 27, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that the patent covering the use of AZD5904 in male...
CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 07, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the fil...
CDT Equity announces AZD5904 progresses into patent cooperation treaty phase
CDT Equity (CDT) announced that AZD5904, a potent inhibitor of human Myeloperoxidase, originally licensed from AstraZeneca (AZN), has progressed into the patent cooperation treaty phase. A total of 18...
CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 06, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that AZD5904, a potent inhibitor of human Myelopero...
CDT Equity management to meet with Maxim
Meeting to be held on April 28 hosted by Maxim.
CDT Equity files to sell 5.35M shares of common stock for holders
06:08 EDT CDT Equity (CDT) files to sell 5.35M shares of common stock for holders
CDT Equity management to meet with Maxim
Meeting to be held on April 28 hosted by Maxim.
CDT Equity expands multi-pathway value creation strategy across pharma, IP
CDT Equity (CDT) provides a strategic update outlining its positioning as a multi-pathway value creation business spanning a pharmaceutical asset portfolio, proprietary solid-form intellectual propert...
CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today provides a strategic update outlining its positioning as a ...
CDT Notes Sarborg Publication of PRISM Framework Expanding AI
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the p...
CDT Equity Inc trading halted, volatility trading pause
09:30 EDT CDT Equity (CDT) Inc trading halted, volatility trading pause
CDT Equity Inc trading halted, news pending
19:50 EDT CDT Equity (CDT) Inc trading halted, news pending
CDT Equity expands Tapinarof intellectual property portfolio with patent filings
CDT Equity (CDT) announced the filing of two new patent applications that further expand the company’s intellectual property portfolio surrounding tapinarof, a drug currently approved for the treatmen...
CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced the filing of two new patent applications that fu...
CDT Equity announces 1-for-25 reverse stock split
CDT Equity announced that its board of directors has approved a 1-for-25 reverse stock split of the company’s common stock. The company’s stockholders approved future reverse stock splits, their timin...
CDT Equity Inc. Announces Reverse Stock Split
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) announces that its board of directors has approved a 1-for-25 reve...
CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 23, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that it has completed initial signature mapping o...
CDT Equity announces stockholders approved all proposals at Special Meeting
CDT Equity (CDT) announced that all proposals put forth at the Special Meeting of Stockholders of CDT, held on Tuesday, March 17, were duly passed by the stockholders. “Following the…
CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that all proposals put forth at the Special Meetin...
CDT Equity notes Sarborg expansion into rare disease signature intelligence
CDT Equity (CDT) notes the announcement from Sarborg Limited regarding the expansion of its proprietary AI Signature Agent platform through the curation of a rare disease signature database. Sarborg a...
CDT Notes Sarborg Expansion into Rare Disease Signature Intelligence
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 12, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the e...